drug pricing investigation · novartis selected documents . document # citation short description...
TRANSCRIPT
![Page 1: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/1.jpg)
Drug Pricing Investigation
Staff Report Committee on Oversight and Reform
U.S. House of Representatives October 2020
oversight.house.gov
Novartis—Gleevec
Selected Investigation Documents
![Page 2: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/2.jpg)
Novartis Selected Documents Document # Citation Short Description
Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt
Novartis 2 CTRL-0118195, at Slide 3 October 2014 Presentation Excerpt
Novartis 3 CTRL-0007100 2013 Presentation Excerpt
Novartis 4 CTRL-0096280, at Slide 4 November 2012 Presentation Excerpt
Novartis 5 CTRL-0029114, at Slide 1 June 2013 Presentation Excerpt
Novartis 6 CTRL-0007430 July 2013 Emails
Novartis 7 CTRL-0130193, at Slide 8 October 2016 Presentation Excerpt
Novartis 8 CTRL-0027659, at Slide 29 April 2014 Presentation Excerpt
Novartis 9 CTRL-0084047, at Slide 4 July 2015 Presentation Excerpt
Novartis 10 CTRL-0004074 February 2018 Emails
Novartis 11 CTRL-0025801, at Slide 12 January 2015 Presentation Excerpt
Novartis 12 CTRL-0088408, at Page 1 2014 Draft Messaging Document
Novartis 13 CTRL-0061584, at Page 1
Novartis 14 CTRL-0095459, at Slide 19 July 2013 Presentation Excerpt
Novartis 15 CTRL-0092356, at Slide 1 Presentation Excerpt
Financial Analysis
![Page 3: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/3.jpg)
Novartis Document 1
Novartis Document 1
![Page 4: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/4.jpg)
Novartis Document 1
Novartis Document 1
![Page 5: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/5.jpg)
Novartis Document 2
Novartis Document 2
![Page 6: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/6.jpg)
Novartis Document 2
Novartis Document 2
![Page 7: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/7.jpg)
Novartis Document 3
Novartis Document 3
![Page 8: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/8.jpg)
Novartis Document 4
Novartis Document 4
![Page 9: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/9.jpg)
Novartis Document 4
Novartis Document 4
![Page 10: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/10.jpg)
Novartis Document 5
Novartis Document 5
![Page 11: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/11.jpg)
Novartis Document 6
Novartis Document 6
![Page 12: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/12.jpg)
Novartis Document 6
Novartis Document 6
![Page 13: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/13.jpg)
Novartis Document 7
Novartis Document 7
![Page 14: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/14.jpg)
NPC092020_CTRL0130200
Novartis Document 7
Novartis Document 7
![Page 15: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/15.jpg)
Novartis Document 8
Novartis Document 8
![Page 16: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/16.jpg)
Novartis Document 8
Novartis Document 8
![Page 17: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/17.jpg)
Novartis Document 9
Novartis Document 9
![Page 18: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/18.jpg)
Novartis Document 9
Novartis Document 9
![Page 19: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/19.jpg)
Novartis Document 10
Novartis Document 10
![Page 20: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/20.jpg)
Novartis Document 10
Novartis Document 10
![Page 21: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/21.jpg)
Novartis Document 11
Novartis Document 11
![Page 22: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/22.jpg)
Novartis Document 11
Novartis Document 11
![Page 23: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/23.jpg)
Novartis Document 12
Novartis Document 12
![Page 24: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/24.jpg)
Initiative Name Project Owner Project Timing Divisions IncludedUS15411_Gleevec Packaging
General Medicines:
Continued through 2015 to 2016
US General Medicines US Oncology
Completed by: Reviewed by Finance:
Customer's First Initiative Financial Details - Incremental Revenue
Financial Methodology and Assumptions
Initiative Assumptions
Non-Responsive
Improved packaging can have 2 effects on Gleevec sales.1) Improved packaging can increase adherence.2) Improved packaging can slow generic erosion (impact would occur in 2016).
Financial Calculations2.5 billion x 1% adherence increase x 6 months (2nd half of year) = $12,500,000.
Initiative DescriptionAssessing the impact of the new Gleevec packaging with the blister packs. Key Learnings from the Diovan LOE are leveraged as we prepare for the Gleevec LOE. Key learnings shared on Divoan for the Gleevec packaging to blister pack.
Management Results Calculations
Novartis Document 13
Novartis Document 13
![Page 25: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/25.jpg)
Novartis Document 14
Novartis Document 14
![Page 26: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/26.jpg)
Novartis Document 14
Novartis Document 14
![Page 27: Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt Novartis 2 CTRL-0118195,](https://reader035.vdocuments.net/reader035/viewer/2022071212/6024cfff07d2c33792420587/html5/thumbnails/27.jpg)
Novartis Document 15
Novartis Document 15